GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study

GLP-1 receptor agonists continue showing their therapeutic potential beyond obesity and diabetes, with a new study indicating that the drug class could significantly lower the risk of several cancers.

The study, published Friday in JAMA Network Open, drew from the electronic health records of 113 million patients across the U.S., of whom nearly 1.7 million were taking GLP-1 analogs for type 2 diabetes. These patients had no history of obesity-associated cancers (OAC). As comparators, the researchers looked at patients who were treated with insulin.